Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Price-to-Owner-Earnings

: 133.91 (As of Today)

View and export this data going back to 2006. Start your Free Trial

As of today (2024-04-23), Catalyst Pharmaceuticals's share price is $14.73. Catalyst Pharmaceuticals's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.11. It's Price-to-Owner-Earnings for today is 133.91.

The historical rank and industry rank for Catalyst Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

CPRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.6 Med: 13.85 Max: 156.06
Current: 135.09

During the past 13 years, the highest Price-to-Owner-Earnings of Catalyst Pharmaceuticals was 156.06. The lowest was 4.60. And the median was 13.85.

CPRX's Price-to-Owner-Earnings is ranked worse than
85.23% of 176 companies
in the Biotechnology industry
Industry Median: 32.26 vs CPRX: 135.09

As of today (2024-04-23), Catalyst Pharmaceuticals's share price is $14.73. Catalyst Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.61. Therefore, Catalyst Pharmaceuticals's PE Ratio for today is 24.15.

As of today (2024-04-23), Catalyst Pharmaceuticals's share price is $14.73. Catalyst Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $0.61. Therefore, Catalyst Pharmaceuticals's PE Ratio without NRI for today is 24.15.

During the past 13 years, Catalyst Pharmaceuticals's highest PE Ratio without NRI was 62.22. The lowest was 4.30. And the median was 14.52.

Catalyst Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Catalyst Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Owner-Earnings

Get a 7-Day Free Trial

12.98

4.99

13.82

20.81

154.22

Catalyst Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Owner-Earnings	Get a 7-Day Free Trial															20.81	18.02	14.04	-	154.22

Competitive Comparison

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Catalyst Pharmaceuticals Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Price-to-Owner-Earnings falls into.

Catalyst Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Catalyst Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	14.73	/	0.11
	=	133.91

Catalyst Pharmaceuticals (NAS:CPRX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

Catalyst Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

Catalyst Pharmaceuticals (Catalyst Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (NAS:CPRX) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

CN2:Germany

Address

355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134

Website

https://www.catalystpharma.com

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Executives

Molly Harper	director	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Alicia Grande	officer: Chief Accounting Officer	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Gary Ingenito	officer: Chief Medical Officer	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Steve Miller	officer: VP Development & Management	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Patrick J Mcenany	director, 10 percent owner, officer: President and Chief Executive	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Carmen Jeffrey Del	officer: Chief Commercial Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Brian Elsbernd	officer: Chief Compliance/Legal Officer	355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134
Philip H Coelho	director	C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Charles B O'keeffe	director	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134
Donald A Denkhaus	director	355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134
Preethi Sundaram	officer: Chief Product Devel. Officer	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134
Daniel Brennan	officer: Chief Commercial Officer	C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286
M Douglas Winship	officer: V.P. of Regulatory Operations	220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134